This inventor holds 1 USPTO granted patent. Top assignee: Cellaster, Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Mi Hyeon Jeong: Innovator in Cancer Research
Introduction
Mi Hyeon Jeong is a prominent inventor based in Jeonju-si, South Korea. She has made significant contributions to the field of cancer research, particularly through her innovative work on the EPB41L5 protein. Her research has the potential to impact cancer prognosis and treatment.
Latest Patents
Mi Hyeon Jeong holds a patent for the "Epitope of EPB41L5, and monoclonal antibody." This patent reveals the TGFβ/Smad3/EPB41L5 molecular mechanism's effect on cancer cells. It highlights that high expression of EPB41L5 correlates with poor overall survival in cancer patients. This finding positions EPB41L5 as a potential prognostic marker for cancer. The patent specifies an epitope of EPB41L5, allowing it to be recognized as an antigen. It also relates to an antibody or fragment that specifically binds to this epitope. The antibody may serve as a therapeutic agent for EPB41L5-related cancer.
Career Highlights
Mi Hyeon Jeong is associated with Cellaster, Inc., where she continues her research and development efforts. Her work is crucial in advancing the understanding of cancer biology and potential therapeutic interventions.
Collaborations
Mi Hyeon Jeong collaborates with notable colleagues, including Kyung Chul Choi and Ho Geun Yoon. These partnerships enhance the research output and innovation in her field.
Conclusion
Mi Hyeon Jeong's contributions to cancer research through her patent on EPB41L5 exemplify her commitment to advancing medical science. Her work holds promise for improving cancer prognosis and treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile